Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00826267 · ClinicalTrials.gov registry record · Phase 2
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00826267 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 29 participants.
The verdict
NCT00826267, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
An open-label, randomized three-arm Phase II trial to explore the efficacy of BIBW 2992 as a single agent versus lapatinib versus trastuzumab in patients with HER2-positive treatment-naïve Stage IIIa locally advanced breast cancer. Additional information will be obtained on the safety profile and pharmacokinetics of BIBW 2992.
Interventions
- DRUG trastuzumab
- DRUG lapatinib
- DRUG BIBW 2992
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00826267
The ClinicalTrials.gov registry entry for NCT00826267 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which trastuzumab is the first listed.
NCT00826267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00826267 about?
NCT00826267 is a clinical study titled "6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab". An open-label, randomized three-arm Phase II trial to explore the efficacy of BIBW 2992 as a single agent versus lapatinib versus trastuzumab in patients with HER2-positive treatment-naïve Stage IIIa locally advanced breast cancer. Additional information will be obtained on the safety profile and ph...
What is the current status of trial NCT00826267?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2009-01.
What interventions are being tested in trial NCT00826267?
The interventions under investigation include: trastuzumab (DRUG), lapatinib (DRUG), BIBW 2992 (DRUG).
Who is sponsoring clinical trial NCT00826267?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.